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What’s Next for Diabetes Prevention?
R
ecent estimates of the prevalence
of diabetes and prediabetes under-
score that no community is being
spared from this ever-advancing, non-
communicable disease (1). Given that
many individuals with these conditions
are going to experience the long-term,
ravaging outcomes of hyperglycemia,
there is a continued and pressing need
to develop approaches that will prevent
the development and progression of di-
abetes as well as its micro- and macro-
vascular complications.
The last two decades have witnessed
the introduction of a number of new
classes of medications to treat diabetes
and the reﬁnement of others. We have
also learned the beneﬁts of more aggres-
sive glucose lowering so that today in-
terventions are frequently commenced
earlier, and many patients are rapidly
placed on more than a single agent. The
focus on earlier intervention has also
grown out of the recognition that the
glucose elevation characterizing type 2
diabetes does not occur suddenly, but
rather is a slow and progressive process
with the pathophysiology well estab-
lished at a time when the glucose levels
have not yet reached the diagnostic thresh-
olds (2). Thus, impaired glucose metabo-
lism and diabetes represent a continuum
and both are amenable to therapy.
Intervening to prevent the develop-
ment of diabetes has been a focus of a
number of studies over the last decade.
In these, both lifestyle modiﬁcation and
medications have been used and have, in
general, been successful in delaying the
onset of the disease. Lifestyle modiﬁ-
cation reduces the risk of developing
diabetes by over 50% (3,4),withdifferent
classes of medications having more vari-
able impact (4–8). The greatest beneﬁt
from pharmacological intervention oc-
curs with the thiazolidinediones (6–8),
which have been shown to be as good, if
not better, than lifestyle intervention.
In this issue of Diabetes Care,
Retnakaran et al. (9) provide additional
information about the effectiveness of
pharmacologic intervention to prevent
progression to diabetes from the Canadian
Normoglycemia Outcome Evaluation
(CANOE)Trial.TheCANOEinvestigators
treated individuals with impaired glucose
tolerance with a low-dose combination
of metformin and the thiazolidinedione
rosiglitazone and demonstrated a reduc-
tion in the risk of developing diabetes
(10), similar in magnitude to that seen
with larger doses of thiazolidinedione
monotherapy. The current report provides
further information on glucose levels, in-
sulin sensitivity, and b-cell function over
the course of the study. As expected, glu-
cose levels fell with combination therapy,
the nadir being reached at 12 months, but
thereafter they increased at a rate equiva-
lent to that inthe placebo group. This pat-
tern is reminiscent of what was observed
in the UK Prospective Diabetes Study
(UKPDS)(11,12),anditwasalsoobserved
in the Diabetes Prevention Program (DPP)
with both the lifestyle and metformin in-
terventions (4). However, it differs from
what was reported in two large studies of
diabetes prevention with thiazolidinediones
(7,8) and in A Diabetes Outcome Preven-
tionStudy(ADOPT)inwhichrosiglitazone
w a sc o m p a r e dw i t ht w oo t h e rg l u c o s e -
lowering agents, glyburide and metfor-
min (13). In these latter three studies,
progression of glycemia beyond a year
was slower with thiazolidinedione therapy
compared with either placebo or any of
t h ea c t i v ec o m p a r a t o r s( 7 , 8 , 1 3 ) ,s u g g e s t -
ing a possible modiﬁcation of the under-
lying disease process.
As thiazolidinediones have been
shown to be more durable than other
agents,theﬁndinginCANOEofaparallel
increase in glucose levels on therapy
compared with placebo is somewhat of
a surprise. There are at least two possi-
ble explanations for this outcome using
combination therapy. First, the dose of
rosiglitazone used in this prevention study
waslessthan themaximaldose,whichwas
what was used when thiazolidinedione
monotherapy was studied for diabetes
prevention (7,8). Second, the effect of
metformin in preventing progression to
diabetes appears to be simply that of
active glucose lowering as its prevention
effect wanes rapidly after stopping the
medication (14). Other explanations may
also be offered, but at this time there is no
clear answer.
Is it possible to truly prevent diabetes
or is this just idealism? At this time, this
has to continue to be the goal. Clearly,
primarypreventionbyaddressingsocietal
issues related to obesity would be best,
and we believe greater effort by authori-
ties at the local, national, and inter-
national levels is needed and could stem
the tide of obesity and with it diabetes.
Further, for proﬁt organizations need to
make a concerted effort to put the health
of the community at the forefront. This
may seem somewhat idealistic, but we
believe the lessons learned from tobacco
cessation provide a foundation for a con-
certed multilevel effort (15).
In the meanwhile, we must also not
lessen our efforts to ﬁnd interventions
that may truly prevent the progression
from impaired glucose metabolism to
diabetes. Such interventions should ide-
ally halt the disease process so that after
withdrawal, progression to diabetes no
longer occurs. This goal would take us be-
yond what we already are able to achieve
with lifestyle and thiazolidinediones that
demonstrate an effect to delay the onset
while treatment is ongoing, but do not
totally halt disease progression. In the
Finnish Diabetes Prevention Study (DPS),
there was a legacy effect so that 3 years
after stopping the lifestyle intervention,
despite ongoing development of dia-
betes in subjects in both the interven-
tion and control groups, the lifestyle
group still exhibited a 43% reduction in
relative risk (16). In the DPP and the
Diabetes REduction Assessment with
ramipril and rosiglitazone Medication
(DREAM) study, after discontinuation
of the thiazolidinedione, there was again a
lower cumulative incidence of diabetes in
keeping with a legacy effect (6,17). How-
ever, the success with thiazolidinediones
comes at a price with weight gain, edema,
andincreasedriskofbonefractures(13,18).
Thus, alternatives are needed. The recent
development of incretin-based therapies
and the successes observed in glucose
lowering with bariatric surgery offer
hope that true prevention may be possible.
Another aspect of the article by
Retnakaran et al. raises an interesting ques-
tion. How good are our assessments of
insulin sensitivity and b-cell function? As
with the ﬂurry of new medications in the
past 20 years or so, there has been a ﬂood
of new approaches to measure these pa-
rameters in order to gain better insight
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many instances what these methods are
estimating is unknown. They are often
used in inappropriate circumstances and
frequently have not been well validated.
Let’s consider a few examples.
1) A commonly used estimate is the in-
sulinogenic index, which measures
the early insulin response following
nutrient ingestion. Little is known
about how this measure relates to
many others, and how it differs with
glucose or a mixed meal, the latter
where amino acid and incretin actions
could be more inﬂuential.
2) The Homeostasis Model Assessment
(HOMA) is widely used, frequently
where there are small sample sizes
and more technically demanding ap-
proaches would be more informative.
Remembering that the HOMA equa-
tion for estimating insulin resistance
was derived for use in fasting humans,
it is not simply transferable to stud-
ies in rodents or to dynamic changes
during a glucose tolerance test (19)!
3) Many different indices have been in-
troduced and applied without any
knowledge of whether they perform
similarly in individuals with normal
glucose tolerance or abnormal glucose
tolerance or whether they are appli-
cable when glucose-lowering medica-
tions are present. Is that the reason
why even though both metformin and
thiazolidinedioneshavebeenshownto
improve insulin sensitivity and b-cell
functioninhumans,Retnakaranetal.’s
study failed to demonstrate an im-
provement in b-cell function (9), or
why in ACT NOW (Actos Now for
Prevention of Diabetes), there was a
failure to demonstrate the expected
improvement in insulin sensitivity (8)?
We would suggest that a reappraisal
of the approaches that are used and
theirapplicationinatechnicallyprecise
manner is necessary if we are going to
gain more insight into the approaches
for preventing diabetes.
So what is next for diabetes preven-
tion? It is clear that progression to dia-
betes is dependent on the ongoing loss
ofb-cellfunctionand possiblereductions
in the number of b-cells. The basis for
thesechangesremainsunclear.Thus,con-
tinued investigation addressing cellular
mechanisms determining b-cell function
and loss is vital. Discoveries of b-cell
genes associated with prediabetes and
type 2 diabetes could well provide in-
sights for discovery. Further, studies
using functional genomics and phar-
macogenomics could be helpful in de-
veloping approaches for preventing
progression. While this work is going
on, clinical studies need to continue.
Whether incretin-based therapies may
improveislethealthwithsustainedbeneﬁt
is something we need to learn sooner
rather than later. Further, combinations
aside from low doses of metformin and
thiazolidinediones may prove superior
in the long term. The excitement being
generated by the observation of diabetes
resolution with bariatric surgery may in
time provide other novel approaches to
test. Thus, there is a great deal to be
learned and more work to be done so
that we can be in a position to witness
the retreat of this scourge of noncommu-
nicable diseases.
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